XTX Topco Ltd Has $210,000 Stock Position in Guardant Health, Inc. (NASDAQ:GH)

XTX Topco Ltd decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 84.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,935 shares of the company's stock after selling 26,522 shares during the quarter. XTX Topco Ltd's holdings in Guardant Health were worth $210,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. NewEdge Advisors LLC raised its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Guardant Health during the 4th quarter worth $61,000. GF Fund Management CO. LTD. purchased a new stake in Guardant Health during the 4th quarter worth $79,000. TD Waterhouse Canada Inc. boosted its position in Guardant Health by 126.2% during the 4th quarter. TD Waterhouse Canada Inc. now owns 2,929 shares of the company's stock worth $89,000 after purchasing an additional 1,634 shares during the period. Finally, CWM LLC boosted its position in Guardant Health by 180.3% during the 1st quarter. CWM LLC now owns 2,296 shares of the company's stock worth $98,000 after purchasing an additional 1,477 shares during the period. Hedge funds and other institutional investors own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GH. Canaccord Genuity Group increased their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Raymond James Financial raised their price target on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Scotiabank raised their price target on shares of Guardant Health from $57.00 to $60.00 and gave the company a "sector outperform" rating in a research note on Thursday, July 31st. Mizuho raised their price target on shares of Guardant Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Friday, June 13th. Finally, UBS Group raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Sixteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $57.50.

Insider Transactions at Guardant Health

In other news, Director Ian T. Clark sold 6,672 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total value of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares of the company's stock, valued at approximately $476,591.38. This represents a 40.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 3,337 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the transaction, the director directly owned 11,150 shares of the company's stock, valued at approximately $526,503. The trade was a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 235,516 shares of company stock worth $11,848,754. 6.10% of the stock is currently owned by company insiders.

Guardant Health Price Performance

Shares of NASDAQ GH traded down $1.48 during trading hours on Friday, hitting $58.88. 3,196,497 shares of the company's stock were exchanged, compared to its average volume of 3,142,794. The company's 50-day moving average price is $49.22 and its 200-day moving average price is $45.54. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $60.68. The stock has a market capitalization of $7.34 billion, a price-to-earnings ratio of -17.58 and a beta of 1.43.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the previous year, the company earned ($0.84) EPS. Guardant Health's revenue for the quarter was up 31.0% compared to the same quarter last year. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.